Clinical-stage biopharmaceutical company Rivus Pharmaceuticals, Inc. announced on Monday positive results from its Phase 2a HuMAIN trial evaluating HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

The study met its primary endpoint, showing statistically significant weight loss with HU6 treatment. Presented at the 2024 Heart Failure Society of America Annual Meeting, the trial also demonstrated improvements in fat mass, visceral fat, and cardiovascular markers. No loss of lean body mass was observed. Secondary endpoints included reductions in systolic and diastolic blood pressure, as well as improved cardiac structure and function.

HU6 was well tolerated, with most adverse events being mild or moderate. No serious treatment-related adverse events were reported. The study enrolled 66 patients, with an average weight of 245 pounds and BMI over 30.